Eye Abnormalities clinical trials
The registry lists 28 studies for Eye Abnormalities across more than 10 countries. 3 are recruiting or about to start. 9 of them are mainly about Eye Abnormalities (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21. Counting its 2 narrower conditions too, such as Hydrophthalmos: 85 studies, 13 open.
Get an email when these change. Save the Eye Abnormalities studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Laboratoires Thea (6) · ProQR Therapeutics (3) · Heidelberg Engineering GmbH (2) · National Eye Institute (NEI) (2) · Editas Medicine, Inc. (2) · Topcon Corporation (1) · Vastra Gotaland Region (1) · TC Erciyes University (1)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Nov 2027Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) · Phase 3 · Laboratoires Thea
Who these studies take
Of the 2 Eye Abnormalities studies recruiting now, 2 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (100%) | 2 (100%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 2 (100%) | 2 (100%) |
| 65 | 2 (100%) | 2 (100%) |
| 75 | 2 (100%) | 2 (100%) |
| 85 | 2 (100%) | 2 (100%) |
Across all 28 studies, recruiting or not: 18% stop at 75 or younger and 18% at 65; 64% take children; 4% are for women only and 0% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 28 of 28. search them.
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)RecruitingNCT06891443Phase 310 countries
- Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneNot yet recruitingNCT07796646Phase 2
- Modeling Ocular Developmental Diseases From 3D Cultures of Optic Vesicle Organoids Derived From hiPSCs of Patients With Ocular MalformationsRecruitingNCT064087011 country
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneActive, not recruitingNCT06627179Phase 210 countries
- The Heidelberg Engineering BI US Evaluation StudyCompletedNCT035783021 country
- Agreement and Precision StudyCompletedNCT067334281 country
- Extension Study to Study PQ-110-001 (NCT03140969)TerminatedNCT03913130Phase 1/22 countries
- Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)TerminatedNCT05176717Phase 2/32 countries
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)TerminatedNCT05158296Phase 2/34 countries
- Effects of a Combination of Polyphenol-rich Extracts on the Protection of Retinal Cells Against Blue Light in the Prevention of Ocular DiseasesCompletedNCT06004570Not applicable1 country
- Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)CompletedNCT010167561 country
- Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)WithdrawnNCT014586134 countries
- Reading Problems Associated With Central Nervous System (CNS) Pathologies.CompletedNCT049377251 country
- Single Ascending Dose Study in Participants With LCA10Status unknownNCT03872479Phase 1/21 country
- The Heidelberg Engineering ANTERION Imaging Agreement StudyCompletedNCT040688181 country
- Natural History Study of CEP290-Related Retinal DegenerationCompletedNCT033960424 countries
- Eye and Growth in Adolescents Born Moderate-to-late PretermCompletedNCT041901471 country
- International Cohort Study of Children Born to Women Infected With Zika Virus During PregnancyCompletedNCT041187384 countries
- Relation Between Oculocardiac Reflex and LaryngospasmStatus unknownNCT053398801 country
- Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GeneCompletedNCT03780257Phase 1/23 countries
- An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.Status unknownNCT04855045Phase 2/37 countries
- A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)Active, not recruitingNCT03913143Phase 2/39 countries
- Independent Prescribing Optometrists in Acute Ophthalmic ServicesCompletedNCT025850631 country
- Study of the Effectiveness of Ozurdex for the Control of UveitisCompletedNCT02049476Phase 41 country
- Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian FailureCompletedNCT004717311 country
- The Stroke Vision App: A Screening Tool for Visual StrokeStatus unknownNCT02539381Not applicable1 country
- Epidemiological Profile of Ophthalmological Care in the Public Service in BrazilCompletedNCT017404661 country
- Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and LensCompletedNCT000011611 country